In 2022, the U.S. Department of Justice (DOJ) continued progressing toward prepandemic levels of enforcement activity. The federal False Claims Act (FCA) remains DOJ’s favorite tool to address alleged healthcare fraud, but other federal and state enforcement authorities have increasingly demonstrated interest in using the tools at their disposal, including antitrust laws, to target the healthcare industry. Below are areas the government is likely to view as particularly attractive targets in the coming year.
What Life Sciences Companies Can Expect for Enforcement in 2023
Feb 07, 2023
Posted by Sidley Austin